All data are based on the daily closing price as of July 18, 2025
s

Synmosa Biopharma

4114.TWO
1.16 USD
-0.01
-0.85%

Overview

Last close
1.16 usd
Market cap
585.12M usd
52 week high
1.29 usd
52 week low
0.88 usd
Target price
1.22 usd

Valuation

P/E
22.5497
Forward P/E
N/A
Price/Sales
3.0077
Price/Book Value
2.0988
Enterprise Value
568.75M usd
EV/Revenue
2.9246
EV/EBITDA
15.6809

Key financials

Revenue TTM
194.47M usd
Gross Profit TTM
84.11M usd
EBITDA TTM
37.55M usd
Earnings per Share
0.05 usd
Dividend
0.02 usd
Total assets
412.15M usd
Net debt
4.53M usd

About

Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches, develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand in Taiwan. The company offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company also provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, sex hormones, and other forms. In addition, it offers contract manufacturing services. The company also exports its products to South Africa, China, Hong Kong, Thailand, Singapore, Malaysia, and other countries. Synmosa Biopharma Corporation was founded in 1970 and is based in Taipei, Taiwan.
  • Symbol
    4114.TWO
  • Exchange
    TWO
  • Isin
    TW0004114004
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Banson Lin
  • Headquarter
    Taipei
  • Web site
    https://www.synmosa.com.tw
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top